UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Main results already published
Unique ID issued by UMIN UMIN000043452
Receipt No. R000049617
Scientific Title Comparison of adverse events in esophageal cancer patients treated with definitive CRT using between 3DCRT and VMAT combination
Date of disclosure of the study information 2021/06/30
Last modified on 2021/02/26

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Evaluation and prospects for the introduction of VMAT for the purpose of reducing pericardial effusion after radical CRT for esophageal cancer
Acronym Evaluation of cardiac VMAT in CRT for esophageal cancer
Scientific Title Comparison of adverse events in esophageal cancer patients treated with definitive CRT using between 3DCRT and VMAT combination
Scientific Title:Acronym Adverse events of VMAT in thoracic CRT
Region
Japan

Condition
Condition Thoracic esophageal squamous cell carcinoma
Classification by specialty
Gastroenterology Radiology
Classification by malignancy Malignancy
Genomic information NO

Objectives
Narrative objectives1 Demonstrate that VMAT can reduce pericardial effusion cases.
Basic objectives2 Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes Dosimetric analyses by irradiation methods reveals observations regarding pericardial effusion after chemoradiation
Key secondary outcomes

Base
Study type Observational

Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
40 years-old <=
Age-upper limit
80 years-old >=
Gender Male and Female
Key inclusion criteria Thoracic esophageal squamous cell carcinoma
Treated with definitive CRT
Given boost 9Gy after 50.4Gy ENI
Key exclusion criteria Age is over 80 years old
Chemotherapy cannot be given due to complications
Target sample size 120

Research contact person
Name of lead principal investigator
1st name Miyako
Middle name
Last name Myojin
Organization Keiyukai Sapporo Hospital
Division name Devision of Radiation Oncology
Zip code 0030027
Address Kita1-1, Hondori14, Shiroishi-ku, Sapporo, Japan
TEL 0118632101
Email miyako98kazm@gmail.com

Public contact
Name of contact person
1st name Miyako
Middle name
Last name Myojin
Organization Keiyukai Sapporo Hospital
Division name Division of radiation oncology
Zip code 0030027
Address ita 1-1, Hondori 14, shiroishi-ku, Sapporo
TEL 0118632101
Homepage URL
Email miyako98kazm@gmail.com

Sponsor
Institute Keiyukai Sapporo Hospital
Institute
Department

Funding Source
Organization Keiyukai Sapporo Hospital
Organization
Division
Category of Funding Organization Other
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization Keiyukai Sapporo Hospital
Address Kita 1-1, Hondori 14, shiroishi-ku, Sapporo
Tel 0118632101
Email miyako98kazm@gmail.com

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions 恵佑会札幌病院 (北海道)

Other administrative information
Date of disclosure of the study information
2021 Year 06 Month 30 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled 158
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Main results already published
Date of protocol fixation
2012 Year 04 Month 01 Day
Date of IRB
2020 Year 05 Month 08 Day
Anticipated trial start date
2012 Year 04 Month 05 Day
Last follow-up date
2021 Year 06 Month 29 Day
Date of closure to data entry
2021 Year 07 Month 12 Day
Date trial data considered complete
2021 Year 07 Month 26 Day
Date analysis concluded
2021 Year 07 Month 31 Day

Other
Other related information Observation is required for at least one year. Logistic regression analysis was performed on patients with pericardial effusion and interstitial pneumonia, excluding those who died within 1 year due to tumors without any adverse events, and significant clinical factors were analyzed. If any of them are related to the radiation therapy plan, the heart / lung
Look for significant factors in the dosimetric parameters. For significant factors, ROC analysis is used to determine the cut-off value for each adverse event

Management information
Registered date
2021 Year 02 Month 26 Day
Last modified on
2021 Year 02 Month 26 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000049617

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.